A gruesome potential side effect of stem cell or bone marrow transplants in oncology patients may soon meet its match in AbbVie’s Imbruvica, which has been accepted for review by the FDA for chronic graft-versus-host disease.
Pfizer said in a release that it has enhanced its stable of oncology therapies with the March 31 announcement that the FDA has expanded the drugmaker's Ibrance medication for treatment of metastatic breast cancer in post-menopausal women.
Patients suffering from multiple myeloma, a cancer of the blood cells, may soon get a new treatment option if officials from the U.S. Food and Drug Administration and the European Medicines Agency expand XGEVA to treat the illness.
The nominee to lead the Food and Drug Administration faced questions today over his business connections to health care and pharmaceutical companies and promised lawmakers he would be an "impartial and passionate advocate for public health."
Dupixent (dupilumab), an injectable drug from Sanofi and Regeneron Pharmaceuticals Inc. used to treat moderate to severe atopic dermatitis (AD), has been approved by the Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) has sent AstraZeneca a complete response letter (CRL) from the regulatory board in response to the development of sodium zirconium cyclosilicate, a drug designed to treat hyperkalaemia.
Merck and Pfizer Inc. said the U.S. Food and Drug Administration (FDA) has agreed to review three New Drug Applications for medications containing ertugliflozin that treat glycemic control in adults with type 2 diabetes.
Alere Inc. has announced that its respiratory syncytial virus test has been granted a Clinical Laboratory Improvement Amendments waiver by the Food and Drug Administration, paving the way for the test to be available to doctors, walk-in clinics and emergency rooms.